The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: Pathophysiology of voiding dysfunction and pharmacological therapy

Journal of Pharmacological Sciences

Volumn 112, Issue 2, 2010, Pages 121-127

  Takeda, Masayuki ^a   Araki, Isao ^a   Mochizuki, Tsutomu ^a   Nakagomi, Hiroshi ^a   Kobayashi, Hideki ^a   Sawada, Norifumi ^a   Zakohji, Hidenori ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Lower urinary tract symptoms (LUTS); Pharmacotherapy; Voiding dysfunction

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; AMINOGLYCOSIDE; ANTIANDROGEN; BACLOFEN; BENZODIAZEPINE; BETA 3 ADRENERGIC RECEPTOR; BETHANECHOL; BOTULINUM TOXIN; BOTULINUM TOXIN A; CHOLINERGIC RECEPTOR STIMULATING AGENT; DANTROLENE; DISTIGMINE; DUTASTERIDE; FINASTERIDE; METOCLOPRAMIDE; MUSCARINIC RECEPTOR; NITRIC OXIDE; OPIATE ANTAGONIST; PHOSPHODIESTERASE INHIBITOR; PROSTAGLANDIN;

BLADDER; BLADDER EMPTYING; DETRUSOR MUSCLE; HUMAN; MICTURITION DISORDER; MICTURITION REFLEX; OVERACTIVE BLADDER; PROSTATE HYPERTROPHY; SHORT SURVEY; SYMPATHETIC TONE; URETHRA STRICTURE;

EID: 77249097978     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.09R17FM     Document Type: Short Survey

References (53)

1. Andersson KE, Appell R, Cardozo L, Chapple C, Drutz H, Fourcroy J, et al. Pharmacological treatment of urinary incontinence. In: Abrams P, Cardozo L, Khoury S, Wein A, editors. 3rd International Consultation on Incontinence. Plymouth, UK: Health Publications; 2005. p. 809-854.
2. Wein AJ. Pathophysiology and classification of voiding dysfunction. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Campbell-Walsh urology, 9th ed. Philadelphia: Saunders Elsevier; 2007. p. 1973-1985.
3. Wein AJ. Lower urinary tract dysfunction in neurologic injury and disease. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Campbell-Walsh urology, 9th ed. Philadelphia: Saunders Elsevier; 2007. p. 2011-2045.
4. de Groat WC. Anatomy and physiology of the lower urinary tract. Urol Clin North Am. 1993;20:383-401.
5. de Groat WC, Yoshimura N. Pharmacology of the lower urinary tract. Annu Rev Pharmacol Toxicol. 2001;41:691-721.
6. Wein AJ, Rovner ES. Pharmacologic management of urinary incontinence in women. Urol Clin North Am. 2002;29:537-550,viii.
7. Andersson KE, Arner A. Urinary bladder contraction and relaxation: physiology and pathophysiology. Physiol Rev. 2004;84: 935-986.
8. Andersson KE. Antimuscarinics for treatment of overactive bladder. Lancet Neurol. 2004;3:46-53.
9. Thomas K, Chow K, Kirby RS. Acute urinary retention: a review of the aetiology and management. Prostate Cancer Prostatic Dis. 2004;7:32-37.
10. Wein AJ. Classification of neurogenic voiding dysfunction. J Urol. 1981;125:605-609.
11. Sawada N, Yao J, Hiramatsu N, Hayakawa K, Araki I, Takeda M, et al. Involvement of hypoxia-triggered endoplasmic reticulum stress in outlet obstruction-induced apoptosis in the urinary bladder. Lab Invest. 2008;88:553-563.
12. Brown JH, Taylor P. Muscarinic receptor agonists and antagonists. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, editors. Goodman and Gilman's The pharmacological basis of therapeutics, 9th ed. New York: McGraw-Hill; 1996. p. 183-200.
13. Finkbeiner AE. Is bethanechol chloride clinically effective in promoting bladder emptying? A literature review. J Urol. 1985;134:443-449.
14. Barendrecht MM, Oelke M, Laguna MP, Michel MC. Is the use of parasympathomimetics for treating an underactive urinary bladder evidence-based? BJU Int. 2007;99:749-752.
15. Mitchell WC, Venable DD. Effects of metoclopramide on detrusor function. J Urol . 1985;134:791-794.
16. Andersson KE. Advances in the pharmacological control of the bladder. Exp Physiol. 1999;84:195-213.
17. Andersson KE. Changes in bladder tone during filling: pharmacological aspects. Scand J Urol Nephrol Suppl. 1999;201:67-72; discussion 76-99.
18. Andersson KE, Appell R, Cardozo L. Pathways for relaxation of detrusor smooth muscle. In: Baskin L, Hayward SW, editors. Advances in bladder research. New York: Plenum; 1999. p. 193-200.
19. Schroder A, Newgreen D, Andersson KE. Detrusor responses to prostaglandin E2 and bladder outlet obstruction in wild-type and Ep1 receptor knockout mice. J Urol. 2004;172:1166-1170.
20. Wang X, Momota Y, Yanase H, Narumiya S, Maruyama T, Kawatani M. Urothelium EP1 receptor facilitates the micturition reflex in mice. Biomed Res. 2008;29:105-111.
21. Zderic SA, Chacko S, Disanto ME, Wein AJ. Voiding function: relevant anatomy, pharmacology, and molecular aspects. In: Gillenwater JY, Grayhack JT, Howards SS, Michell ME, editors. Adult and pediatric urology, 4th ed. New York; Lippincott Williams & Wilkins; 2001. p. 1897-2010.
22. Docherty JR. Subtypes of functional alpha1- and alpha2-adrenoceptors. Eur J Pharmacol. 1998;361:1-15.
23. Harada K, Fujimura A. Clinical pharmacology of alpha1A selective and nonselective alpha1-blockers. BJU Int. 2000;86 Suppl 2:31-34; discussion 34-35.
24. Schwinn DA, Michelotti GA. alpha1-adrenergic receptors in the lower urinary tract and vascular bed: potential role for the alpha1d subtype in filling symptoms and effects of ageing on vascular expression. BJU Int. 2000;85 Suppl 2:6-11.
25. Andersson KE, Wein AJ. Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence. Pharmacol Rev. 2004;56:581-631.
26. Gaines KK. Dutasteride (Avodart): new 5-alpha-reductase inhibitor for treating BPH. Urol Nurs. 2003;23:218-220.
27. Tsukamoto T, Endo Y, Narita M. [Assessment of recommended dose of dutasteride on Japanese men with benign prostatic hyperplasia: a randomized, double-blind, placebo-controlled, parallelgroup, dose response study]. Hinyokika Kiyo . 2009;55:209-214. (in Japanese)
28. Miller J, Tarter T. Combination therapy with dutasteride and tamsulosin for the treatment of symptomatic enlarged prostate. Clin Interv Aging. 2009;4:251-258.
29. Keam SJ, Scott LJ. Dutasteride: a review of its use in the management of prostate disorders. Drugs. 2008;68:463-485.
30. Andersson KE, Persson K. The L-arginine/nitric oxide pathway and non-adrenergic, non-cholinergic relaxation of the lower urinary tract. Gen Pharmacol. 1993;24:833-839.
31. Takeda M, Lepor H. Nitric oxide synthase in dog urethra: a histochemical and pharmacological analysis. Br J Pharmacol. 1995;116:2517-2523.
32. Reitz A, Bretscher S, Knapp PA, Muntener M, Wefer B, Schurch B. The effect of nitric oxide on the resting tone and the contractile behaviour of the external urethral sphincter: a functional urodynamic study in healthy humans. Eur Urol. 2004;45:367-373.
33. Reitz A, Knapp PA, Muntener M, Schurch B. Oral nitric oxide donors: a new pharmacological approach to detrusor-sphincter dyssynergia in spinal cord injured patients? Eur Urol. 2004;45: 516-520.
34. Ehren I, Adolfsson J, Wiklund NP. Nitric oxide synthase activity in the human urogenital tract. Urol Res. 1994;22:287-290.
35. Burnett AL, Maguire MP, Chamness SL, Ricker DD, Takeda M, Lepor H, et al. Characterization and localization of nitric oxide synthase in the human prostate. Urology. 1995;45:435-439.
36. Takeda M, Tang R, Shapiro E, Burnett AL, Lepor H. Effects of nitric oxide on human and canine prostates. Urology. 1995;45: 440-446.
37. Uckert S, Kuthe A, Jonas U, Stief CG. Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol. 2001;166: 2484-2490.
38. Uckert S, Sormes M, Kedia G, Scheller F, Knapp WH, Jonas U, et al. Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue. Urology. 2008;71:526-530.
39. Tinel H, Stelte-Ludwig B, Hutter J, Sandner P. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. BJU Int. 2006;98:1259-1263.
40. Kaplan SA, Gonzalez RR, Te AE. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol. 2007;51: 1717-1723.
41. McVary KT, Monnig W, Camps JL Jr, Young JM, Tseng LJ, van den Ende G. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol. 2007;177: 1071-1077.
42. McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM, et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2007;177:1401-1407.
43. Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol. 2008;180:1228-1234.
44. Bloom FE. Neurotransmission and the central nervous system. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, editors. Goodman and Gilman's The pharmacological basis of therapeutics, 9th ed. New York: McGraw-Hill; 1996. p. 317-340.
45. Hobbs WR, Rall TW, Verdoorn TA. Hypnotics and sedatives: Ethanol. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, editors. Goodman and Gilman's The pharmacological basis of therapeutics, 9th ed. New York: McGraw-Hill; 1996. p. 401-428.
46. Murdock MM, Sax D, Krane RJ. Use of dantrolene sodium in external sphincter spasm. Urology. 1976;8:133-137.
47. Hackler RH, Broecker BH, Klein FA, Brady SM. A clinical experience with dantrolene sodium for external urinary sphincter hypertonicity in spinal cord injured patients. J Urol. 1980;124: 78-81.
48. Simpson LL. Identification of the major steps in botulinum toxin action. Annu Rev Pharmacol Toxicol. 2004;44:167-193.
49. Dykstra DD, Sidi AA. Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study. Arch Phys Med Rehabil. 1990;71:24-26.
50. Munchau A, Bhatia KP. Uses of botulinum toxin injection in medicine today. BMJ. 2000;320:161-165.
51. Cruz F, Silva C. Botulinum toxin in the management of lower urinary tract dysfunction: contemporary update. Curr Opin Urol. 2004;14:329-334.
52. Rackley R, Abdelmalak J. Urologic applications of botulinum toxin therapy for voiding dysfunction. Curr Urol Rep. 2004;5:381-388.
53. Sahai A, Khan M, Fowler CJ, Dasgupta P. Botulinum toxin for the treatment of lower urinary tract symptoms: a review. Neurourol Urodyn. 2005;24:2-12.